Physician
Psychiatry
Dr. Richard E. Kast, MD
Richard E. Kast, MD is an expert in the field of Psychiatry. He attended University of Copenhagen Medical School. Richard Kast is a published doctor as well. He has 100 publications published. The latest was: Crohn's disease remission with phenelzine treatment. He accepts Medicare payments and is registered with Medicare.gov.
Publications
- Oxidizing to death: Disulfiram for cancer cell killing.
- [Corrigendum] Temozolomide-induced modification of the CXC chemokine network in experimental gliomas.
- Glioblastoma treatment using perphenazine to block the subventricular zone's tumor trophic functions.
- A conceptually new treatment approach for relapsed glioblastoma: Coordinated undermining of survival paths with nine repurposed Drugs (CUSP9) by the International Init...
- Why dapsone stops seizures and may stop neutrophils' delivery of VEGF to glioblastoma.
- Erlotinib in Glioblastoma - Lost in Translation?
- Temozolomide modifies caveolin-1 expression in experimental malignant gliomas in vitro and in vivo.
- Progressive multifocal leukoencephalopathy: what's new?
- Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells: consideration of triamterene to treat...
- Three paths to better tyrosine kinase inhibition behind the blood-brain barrier in treating chronic myelogenous leukemia and glioblastoma with imatinib.
- JC virus DNA in healthy brain tissue: a challenge for progressive multifocal leukoencephalopathy diagnosis.
- Lithium and hematology: established and proposed uses.
- Lymphotropic polyomavirus and progressive multifocal leukoencephalopathy.
- Minocycline in cerebral malaria.
- Potential for all-trans retinoic acid (tretinoin) to enhance interferon-alpha treatment response in chronic myelogenous leukemia, melanoma, myeloma and renal cell carc...
- Serotonin receptor 2A blocker (risperidone) has no effect on human polyomavirus JC infection of primary human fetal glial cells.
- Conditioning response to granulocyte colony-stimulating factor via the dipeptidyl peptidase IV-adenosine deaminase complex.
- 5-HT2a inhibitors for progressive multifocal leukoencephalopathy: old Drugs for an old disease.
- JC viremia and multiple sclerosis.
- Dopamine agonists and valvular heart disease.
- Review of evidence that posttransplantation psychiatric treatment commonly affects prolactin levels and thereby influences graft fate.
- Consideration of use of neuraminidase inhibitors such as oseltamivir and zanamivir in IgA nephropathy.
- Bupropion and chronic aphthous ulceration.
- H1-antihistamines.
- Crohn's disease remission on bupropion.
- Bupropion in psoriasis and atopic dermatitis: decreased tumor necrosis factor-alpha?
- Ribavirin in cancer immunotherapies: controlling nitric oxide augments cytotoxic lymphocyte function.
- Erlotinib augmentation with dapsone for rash mitigation and increased anti-cancer effectiveness.
- Mirtazapine may be useful in treating nausea and insomnia of cancer chemotherapy.
- Dementia and statins.
- Therapeutic efficacy of azaindole-1 in experimental pulmonary hypertension.
- Activation of cytosolic phospholipase A2 by transforming growth factor-alpha in HEL-30 keratinocytes.
- Reversal of lithium-related cardiac repolarization delay by potassium.
- Lymphocytes and cells in malignant transformation: similarities and possible relationship between the two cell types.
- Using blood brain barrier disruption by methamphetamine for Drug delivery.
- Epidermal-growth-factor-induced production of phosphatidylAlcohols by HeLa cells and A431 cells through activation of phospholipase D.
- Tumor necrosis factor has positive and negative self regulatory feed back cycles centered around cAMP.
- Non-steroidal anti-inflammatory Drugs might also be pro-inflammatory by increasing tumor necrosis factor.
- Aspirin use in myeloma: a note of caution regarding potential tumour necrosis factor-alpha elevation.
- Cancer diagnostic test of Field and Caspary: Part I. Spontaneous aggregation of lymphocytes in saline suspension is blocked by albumin and histone in normals but not i...
- Predominance of autoimmune and rheumatic diseases in females.
- Tiagabine may reduce bruxism and associated temporomandibular joint pain.
- Cancer diagnostic test of Field and Caspary: Part II. A review and interpretation of the collected data.
- Tenofovir, COX inhibitors and zileuton during cancer immunotherapies: up-regulated TNF-alpha increases antigen driven lymphocyte proliferation.
- Glioblastoma invasion, cathepsin B, and the potential for both to be inhibited by auranofin, an old anti-rheumatoid arthritis Drug.
- Improving imatinib delivery to central nervous system.
- Chaperonin 10 for rheumatoid arthritis.
- Acarbose related diarrhea: increased butyrate upregulates prostaglandin E.
- Melanoma inhibition by cyclooxygenase inhibitors: role of interleukin-6 suppression, a putative mechanism of action, and clinical implications.
- Endothelin-1 inhibition by ambrisentan as a potential treatment adjunct after debulking surgery in epithelial ovarian cancer.
- Borage oil reduction of rheumatoid arthritis activity may be mediated by increased cAMP that suppresses tumor necrosis factor-alpha.
- How lithium treatment generates neutrophilia by enhancing phosphorylation of GSK-3, increasing HIF-1 levels and how this path is important during engraftment.
- Central nervous system graft-versus-host disease: consider progressive multifocal leukoencephalopathy among the differential diagnoses.
- A solution to the graft-versus-host problem in bone marrow transplantation to humans.
- Crohn's disease remission with phenelzine treatment.
- Hyaluronate and risperidone for hemorrhagic cystitis.
- Aspirin, TNF-alpha, NFkB, and survival in multiple myeloma: the importance of measuring TNF-alpha.
- Some fibrocystic breast change may be caused by sexually transmitted H. pylori during oral nipple contact: supporting literature and case report of resolution after gu...
- Glioblastoma chemotherapy adjunct via potent serotonin receptor-7 inhibition using currently marketed high-affinity antipsychotic medicines.
- A new chapter opens in anti-inflammatory treatments: the antidepressant bupropion lowers production of tumor necrosis factor-alpha and interferon-gamma in mice.
- Use of FDA approved methamphetamine to allow adjunctive use of methylnaltrexone to mediate core anti-growth factor signaling effects in glioblastoma.
- Glioblastoma: synergy of growth promotion between CCL5 and NK-1R can be thwarted by blocking CCL5 with miraviroc, an FDA approved anti-HIV Drug and blocking NK-1R with...
- Can the therapeutic effects of temozolomide be potentiated by stimulating AMP-activated protein kinase with olanzepine and metformin?
- Cancer chemotherapy and cachexia: mirtazapine and olanzapine are 5-HT3 antagonists with good antinausea effects.
- Doxorubicin cardiomyopathy via TLR-2 stimulation: potential for prevention using current anti-retroviral inhibitors such as ritonavir and nelfinavir.
- Bone density loss in Crohn''s disease: role of TNF and potential for prevention by bupropion.
- Treatment schedules for 5-HT2A blocking in progressive multifocal leukoencephalopathy using risperidone or ziprasidone.
- Evidence of a mechanism by which etanercept increased TNF-alpha in multiple myeloma: new insights into the biology of TNF-alpha giving new treatment opportunities--the...
- Anti- and pro-inflammatory considerations in antidepressant use during medical illness: bupropion lowers and mirtazapine increases circulating tumor necrosis factor-al...
- Remission of Crohn's disease on bupropion.
- Ribavirin in cancer immunotherapies: controlling nitric oxide helps generate cytotoxic lymphocyte.
- Screening of anti-glioma effects induced by sigma-1 receptor ligands: potential new use for old anti-psychiatric medicines.
- Why cerebellar glioblastoma is rare and how that indicates adjunctive use of the FDA-approved anti-emetic aprepitant might retard cerebral glioblastoma growth: a new h...
- Suppressing glioblastoma stem cell function by aldehyde dehydrogenase inhibition with chloramphenicol or disulfiram as a new treatment adjunct: an hypothesis.
- Trazodone generates m-CPP: in 2008 risks from m-CPP might outweigh benefits of trazodone.
- Ritonavir and disulfiram have potential to inhibit caspase-1 mediated inflammation and reduce neurological sequelae after minor blast exposure.
- Acyclovir inhibition of IDO to decrease Tregs as a glioblastoma treatment adjunct.
- Temozolomide-induced modification of the CXC chemokine network in experimental gliomas.
- Profound blockage of CXCR4 signaling at multiple points using the synergy between plerixafor, mirtazapine, and clotrimazole as a new glioblastoma treatment adjunct.
- The Rationale of Targeting Neutrophils with Dapsone during Glioblastoma Treatment.
- Feedback between glial tumor necrosis factor-alpha and gp120 from HIV-infected cells helps maintain infection and destroy neurons.
- Tumor necrosis factor-alpha in hepatitis B: potential role for bupropion.
- Combination of bupropion, paroxetine and quetiapine as adjuvant treatment for multiple myeloma.
- Paroxetine for hepatopulmonary syndrome?
- Bupropion for Blau syndrome.
- Anti-apoptosis function of TNF-alpha in chronic lymphocytic leukemia: lessons from Crohn''s disease and the therapeutic potential of bupropion to lower TNF-alpha.
- Proposal for using small molecule tumor necrosis factor-alpha lowering agents, possibly bupropion, in aplastic anemia.
- Using histamine (H1) antagonists, in particular atypical antipsychotics, to treat anemia of chronic disease via interleukin-6 suppression.
- The atypical antipsychotic agents ziprasidone [correction of zisprasidone], risperdone and olanzapine as treatment for and prophylaxis against progressive multifocal l...
- Bupropion for fatigue and as a tumor necrosis factor-alpha lowering agent in primary biliary cirrhosis.
- Both etanercept and infliximab can elevate tumor necrosis factor (TNF)-alpha and be the cause of treatment related new onset disease: the need to measure circulating T...
- The earliest example of the hyperactivity subtype of attention deficit hyperactivity Disorder (ADHD) in Jan Steen''s ''The Village School'' (c. 1670).
- Glioblastoma: looking at the currently marketed sigma-1 agonists and antagonists.
- Intraperitoneal lavage with imiquimod to eliminate epithelial ovarian cancer micro metastases.
- Consideration of acamprosate for treatment of amyotrophic lateral sclerosis.
- Evidence that amphotericin B mediates reactivation of latent Epstein-Barr virus in Hodgkin''s lymphoma allowing cytotoxicity by acyclovir.
- How influenza''s neuraminidase promotes virulence and creates localized lung mucosa immunodeficiency.
- Bupropion: pharmacology and therapeutic applications.
- Co-administration of ramelton and fluvoxamine to increase levels of interleukin-2.
Procedures Preformed
- Psychiatric Evaluation
- Psychotherapy and Psychophysiological Therapy (incl. Biofeedback)
Conditions Treated
- Adjustment Disorder
- Anxiety
- Bipolar Disorder
- Combination Drug Dependence
- View All
Doctors Specialties
- Family Medicine
- Psychiatry
Accepted Insurances
- Blue Card PPO
- Great West Healthcare-Cigna PPO
Education
-
University of Vermont - Fletcher Allen Health Care -
University of Copenhagen Medical School
Drug Facts
| NPI NUMBER | 1235233644 | |
| NPPES Provider LastName | KAST | |
| NPPES Provider FirstName | RICHARD | |
| NPPES Provider ZIPCode | 054014299 | |
| NPPES Provider State | VT | |
| Specialty Description | Psychiatry | |
| Total Claim Count | 412.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1235233644 |
| Last Name Of The Provider | KAST |
| First Name Of The Provider | RICHARD |
| View All |
